AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%

investors.com/news/technology/abbvie-stock-abbvie-earnings-q3-2025/?src=A00220

leaned hard on Skyrizi, Rinvoq and Botox to offset continued steep declines from Humira and its aesthetics division, an analyst said Friday as AbbVie stock dipped.
Skyrizi, an immunology drug that treats conditions like psoriasis and arthritis, is now AbbVie's biggest moneymaker. In the…

This story appeared on investors.com, 2025-10-31 13:45:58.
The Entire Business World on a Single Page. Free to Use →